busulfan has been researched along with Growth Disorders in 11 studies
Growth Disorders: Deviations from the average values for a specific age and sex in any or all of the following: height, weight, skeletal proportions, osseous development, or maturation of features. Included here are both acceleration and retardation of growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The most common primary cancer was acute lymphoblastic leukemia (22 patients, 31." | 1.56 | Factors predicting endocrine late effects in childhood cancer survivors from a Japanese hospital. ( Kazukawa, I; Kihara, M; Minagawa, M; Mori, K; Shimazaki, S, 2020) |
| "Busulfan was given as a single daily dose." | 1.31 | Growth and endocrine function in children with acute myeloid leukaemia after bone marrow transplantation using busulfan/cyclophosphamide. ( Afify, Z; Clavano-Harding, A; Cowell, CT; Shaw, PJ, 2000) |
| "Data on 181 of 230 patients with aplastic anemia, leukemias, and lymphomas who had BMT before puberty (mean age, 9." | 1.30 | Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by the Working Party for Late Effects-EBMT. ( Bakker, B; Cahn, JY; Cohen, A; Dopfer, R; Esperou, H; Gaiero, A; Kolb, HJ; Leiper, AD; Merlo, F; Rovelli, A; Socié, G; Uderzo, C; van Lint, MT, 1999) |
| " The 30-day survival was 87-100% in mice transplanted after 10-40 mg/kg busulfan and 79% after TBI, but fell to 54% and 33%, respectively, after 80 mg/kg and 100 mg/kg busulfan, suggesting that this latter dosage range represents the LD50 for single-dose busulfan in young C57BL/6 mice given stem cell rescue." | 1.28 | Growth retardation and depigmentation of hair after high-dose busulfan and congenic hematopoietic cell transplantation in mice. ( Farmer, ER; Shinn, C; Wingard, JR; Yeager, AM; Yeager, MJ, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (54.55) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Shimazaki, S | 1 |
| Kazukawa, I | 1 |
| Mori, K | 1 |
| Kihara, M | 1 |
| Minagawa, M | 1 |
| Bernard, F | 1 |
| Auquier, P | 1 |
| Herrmann, I | 1 |
| Contet, A | 1 |
| Poiree, M | 1 |
| Demeocq, F | 1 |
| Plantaz, D | 1 |
| Galambrun, C | 1 |
| Barlogis, V | 1 |
| Berbis, J | 1 |
| Garnier, F | 1 |
| Sirvent, N | 1 |
| Kanold, J | 1 |
| Chastagner, P | 1 |
| Chambost, H | 1 |
| Michel, G | 1 |
| Bakker, B | 2 |
| Oostdijk, W | 1 |
| Bresters, D | 1 |
| Walenkamp, MJ | 1 |
| Vossen, JM | 1 |
| Wit, JM | 1 |
| Giorgiani, G | 1 |
| Bozzola, M | 1 |
| Locatelli, F | 1 |
| Picco, P | 1 |
| Zecca, M | 1 |
| Cisternino, M | 1 |
| Dallorso, S | 1 |
| Bonetti, F | 1 |
| Dini, G | 1 |
| Borrone, C | 1 |
| Le Heup, B | 1 |
| von Bueltzingloewen, A | 1 |
| Bordigoni, P | 1 |
| Sommelet, D | 1 |
| Pierson, M | 1 |
| De Sanctis, V | 1 |
| Galimberti, M | 1 |
| Lucarelli, G | 1 |
| Angelucci, E | 1 |
| Ughi, M | 1 |
| Baronciani, D | 1 |
| Polchi, P | 1 |
| Giardini, C | 1 |
| Vullo, C | 1 |
| Bagni, B | 1 |
| Cohen, A | 1 |
| Rovelli, A | 1 |
| Uderzo, C | 1 |
| van Lint, MT | 1 |
| Esperou, H | 1 |
| Gaiero, A | 1 |
| Leiper, AD | 1 |
| Dopfer, R | 1 |
| Cahn, JY | 1 |
| Merlo, F | 1 |
| Kolb, HJ | 1 |
| Socié, G | 1 |
| Afify, Z | 1 |
| Shaw, PJ | 1 |
| Clavano-Harding, A | 1 |
| Cowell, CT | 1 |
| Ayas, M | 1 |
| Belgaumi, A | 1 |
| Al-Mahr, M | 1 |
| Al-Jefri, A | 1 |
| Solh, H | 1 |
| Leung, W | 1 |
| Yeager, AM | 1 |
| Shinn, C | 1 |
| Farmer, ER | 1 |
| Wingard, JR | 1 |
| Yeager, MJ | 1 |
| Sanders, JE | 1 |
2 reviews available for busulfan and Growth Disorders
| Article | Year |
|---|---|
[Endocrinal sequela in bone marrow transplantations during childhood and adolescence].
Topics: Adolescent; Age Factors; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; Cr | 1993 |
The impact of marrow transplant preparative regimens on subsequent growth and development. The Seattle Marrow Transplant Team.
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Cyclophosphamide; Developmental Disabiliti | 1991 |
9 other studies available for busulfan and Growth Disorders
| Article | Year |
|---|---|
Factors predicting endocrine late effects in childhood cancer survivors from a Japanese hospital.
Topics: Adolescent; Adult; Antineoplastic Agents; Brain Neoplasms; Busulfan; Cancer Survivors; Child; Chroni | 2020 |
Health status of childhood leukemia survivors who received hematopoietic cell transplantation after BU or TBI: an LEA study.
Topics: Adolescent; Busulfan; Cataract; Child; Child, Preschool; Female; Follow-Up Studies; Growth Disorders | 2014 |
Disturbances of growth and endocrine function after busulphan-based conditioning for haematopoietic stem cell transplantation during infancy and childhood.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Body Height; Busulfan; Calcium; Child; Child, Prescho | 2004 |
Role of busulfan and total body irradiation on growth of prepubertal children receiving bone marrow transplantation and results of treatment with recombinant human growth hormone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Height; Bone Marrow Transplantation; Busulfan; | 1995 |
Gonadal function in long term survivors with B thalassemia major following bone marrow transplantation.
Topics: Adolescent; beta-Thalassemia; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Child; Chi | 1993 |
Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by the Working Party for Late Effects-EBMT.
Topics: Adolescent; Adult; Age Factors; Anemia, Aplastic; Body Height; Bone Marrow Transplantation; Busulfan | 1999 |
Growth and endocrine function in children with acute myeloid leukaemia after bone marrow transplantation using busulfan/cyclophosphamide.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan | 2000 |
Allogeneic BMT for infantile acute leukemia: what is the optimal conditioning regimen?
Topics: Acute Disease; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Disease-Free Survival; Etopo | 2002 |
Growth retardation and depigmentation of hair after high-dose busulfan and congenic hematopoietic cell transplantation in mice.
Topics: Animals; Bone Marrow Transplantation; Brain; Busulfan; Growth Disorders; Hair Color; Hematopoietic S | 1992 |